On February 8, 2018, a regular court session on the case to repeal the patent for the company AbbVie’s drug Aluvia was held. The judges were Serhyi Sotnikov, Anatolii Verkhovets and Oleg Ostapenko.
During the previous meeting, on February 6, 2018, AbbVie stated objections to an expert proposed by the Network and offered its specialist in the field of chemistry and pharmaceutics, O. Simurov, who is an employee of the Institute of Endocrinology and Metabolism named after Komisarenko V.P. of the NAMS of Ukraine. Despite the fact that the Network offered its expert who is a Doctor of Medical Science, teacher of organic chemistry at the Bogomolets National Medical University, the court decided to send the patent for examination to the expert proposed by AbbVie.
“We are looking forward to the results, and we hope that the expert proposed by AbbVie will conduct the examination independently,” said the Head of the Coordinating Council of the Network Dmytro Sherembey. “Moreover, this case has a high social value: it is about the life and health of 125 thousand Ukrainian patients. But we are persistent, and we will not stop in our struggle for life.”
According to the procedures, the results of the examination will be ready within 3-4 months.